-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Salvage chemotherapy and autologous stem cell transplantation (auto-SCT) cure approximately 50% of Hodgkin lymphoma (HL) patients
Salvage chemotherapy and autologous stem cell transplantation (auto-SCT) cure approximately 50% of Hodgkin lymphoma (HL) patients
For this purpose, the researchers used a large sample from the EBMT registry to analyze 1781 adult HL patients who relapsed after their first automated SCT between 2006 and 2017
Figure 1: Overall survival of 1781 patients with relapse due to relapsed/refractory classic HL from 2006 to 2017
Figure 1: Overall survival of 1781 patients with relapse due to relapsed/refractory classic HL from 2006 to 2017
Figure 2: Overall survival after relapse improved over time
Figure 2: Overall survival after relapse improved over time
In multivariate analysis, patients who relapsed in recent years and those with a longer interval from transplant to relapse had better OS, while increasing age, poor performance status, bulk disease, extranodal disease, and B symptoms at relapse Have a worse OS with a worse OS
Figure 3: Treatment of recurrence after autologous sct
Figure 3: Treatment of recurrence after autologous sct
Brentuximab vedotin (BV), checkpoint inhibitor (CPI), and second transplant (SCT2; 86% allogeneic) were used in 233, 91, and 330 patients, respectively
The study lacked central review and information on methods for radiological assessment of response to salvage therapy and relied primarily on reporting centres
However, this study is the largest analysis to date evaluating trends over time and predictors of prognosis in recurrent HL after autologous sct
Original source:
Original source:Bazarbachi, A.
Bazarbachi, A.
, Boumendil, A.
, Finel, H.
et al.
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
Leukemia (2022).
https://doi.
org /10.
1038/s41375-022-01563-8.
Bazarbachi, A.
, Boumendil, A.
, Finel, H.
et al.
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
Leukemia (2022).
https://doi.
org/10.
1038/s41375-022-01563-8.
et al.
Leukemia
leave a comment here
